Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Antisecretory Effect of Rabeprazole and Omeprazole in Obese Subjects
NCT01136317Phase 2Completed
- Sponsor
- CHU de Nantes
- Start
- Apr 2010
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of rabeprazole in gastroesophageal reflux disease (GERD) (3 arms), sponsored by CHU de Nantes. Primary endpoint: Percentage of time with gastric pH above 3 during 24 hours. Started Apr 2010; status: completed.
02
Drugs
rabeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT01136317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01136317.